Evelo Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview

Evelo Biosciences

27/07/2021 14:58

* Evelo Biosciences Inc  EVLO.OQ   EVLO.O  is expected to show a
no change in quarterly revenue when it reports results on July
29. 
​* Refinitiv's mean analyst estimate for Evelo Biosciences Inc
is for a loss of 54 cents per share. For the same quarter last
year, the company reported a loss of 63 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Evelo
Biosciences Inc is $21.5​, about 57.7% above​ its last closing
price of $9.10. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.51       -0.51      -0.55     Missed  -8.7
 Dec. 31 2020  -0.59       -0.53      -0.62     Missed  -17.5
 Sep. 30 2020  -0.50       -0.50      -0.45     Beat    10.4​
 Jun. 30 2020  -0.78       -0.78      -0.63     Beat    19.2
 Mar.          -0.72​      -0.73      -0.71     Beat    2.9​
 31​ 2020​                                              
 Dec. 31 2019  -0.62       -0.61      -0.70     Missed  -14.4​
 Sep. 30 2019  -0.62       -0.63      -0.67     Missed  -6.8
 Jun. 30 2019  -0.64       -0.62      -0.65     Missed  -5.2
 This summary was machine generated July 27 at 13:58 GMT.  All
figures in US dollars unless otherwise stated